06 September 2017
Researchers at Epic Sciences and Memorial Sloan Kettering developed and applied a ground-breaking new test for measuring the cellular diversity within tumors, or tumor heterogeneity, through the analysis of single circulating tumor cells (CTCs). To measure tumor heterogeneity, researchers analyzed protein and morphology based biomarkers in single CTCs and quantified degrees of variance among CTCs in blood samples from patients prior to receiving targeted androgen receptor signaling inhibitor (ARSi) therapies, including the blockbuster drugs Zytiga® and Xtandi®, compared to blood samples from patients prior to receiving chemotherapy.
EMA started a survey to understand the awareness about side effects of medicines
06 September 2017
EMA has launched a survey to better understand patients’ and healthcare professionals’ awareness of reporting adverse drug reaction, including for medicines under ‘additional monitoring’. Medicines under additional monitoring are monitored particularly closely by regulatory authorities. They are easily identified by a black inverted triangle displayed in their package leaflet and in the information for healthcare professionals, called the ‘summary of product characteristics’ (SmPC). Healthcare professionals and patients are encouraged to report any suspected adverse reactions.
New device diagnoses and predicts lung problems
06 September 2017
At the Far East Center for Respiratory Physiology and Pathology in Blagoveshchensk, in the Amur region some 7,800km east of Moscow, researchers have come up with a new device to diagnose allergy to cold and a range of dangerous respiratory diseases in patients.
Significant increase in pharmaceutical substances imports this year in Russia
05 September 2017
Russian drugmakers and foreign companies operating in the country have significantly increased the volume of pharmaceutical substances imports this year, a spokesman for Veronika Skvortsova, Russia’s Minister of Health, recently said, reports The Pharma Letter’s local correspondent.
The top 10 biopharma CROs in the world—mid-2017 edition
05 September 2017
Huddled with five employees in a tiny Chapel Hill house, Quintiles Transnational founder Dennis Gillings began breaking down the many things drug companies needed done when testing in humans and started doing them much more reliably than his clients could, and with that, gave rise to the modern CRO industry. The year was 1982 and the company has dominated clinical outsourcing for the 35 years since.
Advanced multiple myeloma drug candidate gets Russian backing
04 September 2017
Primer Capital, a Russian biotech-focused VC fund, has supported the development of a drug candidate by Russian company Hemopharm to help multiple myeloma patients. No deal’s value has been made public. In a message to Marchmont News the fund’s press service said the investment will fund preclinical trials.
‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments
04 September 2017
Scientists at the Fred Hutchinson Cancer Research Center have developed a tool that they believe could address both those shortcomings of CAR-T and other forms of cell engineering. They have invented nanoparticles that deliver proteins to cells, which in turn edit those cells’ genes temporarily. Lead author and bioengineer Matthias Stephan describes it as “hit-and-run” gene therapy, and he believes the technique will streamline the manufacturing of cell-based therapies.
01 September 2017
The United Kingdom life sciences sector has called for (PDF) the government to make changes that help grow Big Biotechs and attract thousands of researchers. Industry leaders put together the wish list to influence an upcoming deal between the sector and an increasingly interventionist government.
Pfizer, Celgene and Roche are climbing pharma VC league table
01 September 2017
Corporate venture capital (CVC) has long been an important source of capital for early-stage biotechs and shows no signs of diminishing, with more and more biopharma companies stepping up their investment activity.
FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis
31 August 2017
The FDA has approved the world’s first CAR-T therapy, giving a green light to Novartis for Kymriah (tisagenlecleucel) in what regulators themselves describe as an historic event.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024